David Planchard, Thoracic Oncologist, Professor at University Paris Saclay and Head of Thoracic Cancer Group at Gustave Roussy, shared LinkedIn post about recent paper he and his colleague authored:
“Things are finally king in NEMs lung…to be continued!
Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors? | JTO Clinical and Research Reports.”
Authors: Mariona Riudavets, David Planchard
Read more about “Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates” on OncoDaily.
